Carl G, Laux G
Psychiatrische Universitätsklinik, Würzburg.
Psychiatr Prax. 1989 Aug;16 Suppl 1:48-50.
13 patients with major depressive disorder, who responded well to the reversible MAO-A-inhibitor moclobemide after unsuccessful initial treatment with tri- or tetracyclic antidepressants were monitored under naturalistic outpatient therapy conditions with moclobemide plasma level control for an average of 7.4 months. Due to depressive relapse moclobemide treatment had to be discontinued for 6 patients. Increased dosages or the addition of a tricyclic antidepressant did not bring about any sufficient improvement. The relapse occurred after an average of 2-3 months of treatment with moclobemide administration. In the case of 7 patients it was possible to discontinue treatment with moclobemide after an average of 9.7 months with an incremental reduction in dosage. Recurring depressive symptoms were counteracted in the case of 2 patients by increasing dosages and adding a tricyclic antidepressant. The patients reported good tolerance of the drug as compared to tri- or tetracyclics.
13名重度抑郁症患者在最初使用三环或四环类抗抑郁药治疗失败后，对可逆性单胺氧化酶-A抑制剂吗氯贝胺反应良好，在自然主义的门诊治疗条件下接受监测，同时控制吗氯贝胺血浆水平，平均监测7.4个月。由于抑郁复发，6名患者不得不停止使用吗氯贝胺治疗。增加剂量或加用三环类抗抑郁药均未带来足够的改善。复发发生在使用吗氯贝胺治疗平均2 - 3个月后。7名患者在平均9.7个月后通过逐渐减少剂量停用了吗氯贝胺治疗。2名患者通过增加剂量和加用三环类抗抑郁药抵消了反复出现的抑郁症状。与三环或四环类药物相比，患者报告该药耐受性良好。
